GUILFORD HURST: Open Payments
NPI 1467779256 · WILMINGTON, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$12,982 in 58 payments from 8 companies in 2025. Trend: 2023 $12,693 · 2024 $9,551 · 2025 $12,982
Speaker / faculty: $6,750Consulting: $4,380Food & beverage: $1,106Travel & lodging: $746
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 27 | $12,433 |
| E.R. Squibb & Sons, L.L.C. | 12 | $145 |
| Otsuka America Pharmaceutical, Inc. | 6 | $138 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $72 |
| Neurocrine BioSciences, Inc. | 3 | $63 |
| Lundbeck LLC | 3 | $56 |
| Teva Pharmaceuticals USA, Inc. | 2 | $45 |
| ABBVIE INC. | 2 | $30 |
Products named: LYBALVI, COBENFY, REXULTI, ARISTADA, CAPLYTA, INGREZZA, ABILIFY ASIMTUFII, VRAYLAR.
Industry payments across DE — which companies pay providers there.
